Case Studies

The Dedicated Center

Outsourcing answer to the innovation and ROI challenge in the Biopharmaceutical Industry.

Released by Syngene International Ltd. 01.13.21

The pharmaceutical industry is facing a sustainability crisis due to dwindling ROI on research and development. Even though the top 20 pharmaceutical companies invested 20.9% of topline revenues into R&D last year, IRR for pharma R&D is already below the cost of capital and is projected to hit zero.

DOWNLOAD TO LEARN MORE>>>>

More Case Studies by Syngene International Ltd.

Case Studies

Your Pre-clinical Toxicology Program Needs a Strat

At Syngene, we have developed a roadmap across pre-IND, IND and NDA that seamlessly integrate the various pre-clinical studies.
359439 01.14.21
Case Studies

Proactive COVID-19 Testing

By identifying COVID-19 positive cases early on, particularly those that are asymptomatic, we can restrict further transmission of this deadly virus.
359441 01.12.21
Case Studies

How Integrated CMC Can Help Expedite Early Phase D

Syngene's 7-phase integrated CMC strategy helps expedite IND/IMPD filings and FIH studies.
359442 01.11.21
Case Studies

Harnessing Targeted Protein Degradation

Read how Syngene's partnership with a leading Biotech company working in the field of cancer therapy grew from one small pilot project to over 100 FTEs today.
359438 01.08.21
Case Studies

The Many Benefits of Outsourcing Stability: A Baxt

Learn why Baxter chose to partner with Syngene for Stability studies, the business flow, governance mechanism and metrics that were implemented.
359437 01.07.21

More Content From Syngene International Ltd.

Solid Dosage/Creams/Ointments

Oral Solid Dose Outsourcing Trends: CMOs Bask in Pill Promise

OSD outsourcing expands as CMOs excel. This is the second of a nine-part series of articles addressing pharmaceutical outsourcing industry trends.

Sponsored Content Released on 03.10.2023
Drug Discovery | R&D

CROs at the High Table of Drug Discovery

Offshoring reaches an inflection point as CROs turn risk-sharing partners in discovery research. This is the first of a nine-part series.

Sponsored Content Released on 01.30.2023
Videobite: Trends Driving Small Molecule Drug Development and Outsourcing

Trends driving small molecule drug development and outsourcing.

Videos Released on 11.28.2022
Targeted Protein Degradation

Syngene has considerable experience solving synthetic chemistry and purification challenges with PROTACS.

Literature / Brochures Released on 01.18.2021
Biologics and Manufacturing

Syngene offers Biologics development and Biomanufacturing solutions in both mammalian and microbial systems.

Literature / Brochures Released on 01.15.2021
Chemical Development

Syngene has full value-chain Process Research and Development (PRD) capabilities for NCEs and advanced intermediates.

Literature / Brochures Released on 01.14.2021
Clinical Development

Syngene supports early-phase to late-phase clinical trials required for drug development programs across a wide range of therapeutic areas.

Literature / Brochures Released on 01.13.2021
Commercial Manufacturing

Syngene supports manufacturing of regulatory starting materials, APIs, HPAPI, NCEs and novel advanced intermediates.

Literature / Brochures Released on 01.12.2021
Formulation Development

Syngene supports both development and manufacturing of Drug Products from early to late stage.

Literature / Brochures Released on 01.11.2021
ICH Stability Studies

One of the largest Stability facilities in Asia, Syngene supports both small and large molecules from early development to CMC filing and commercialization.

Literature / Brochures Released on 01.08.2021
Oligonucleotides

Syngene's services encompass Therapeutic oligonucleotides, Diagnostic Oligonucleotides, Enzymatic synthesis and analytical services.

Literature / Brochures Released on 01.07.2021
Syngene InstaVisit

...

Videos Released on 01.07.2021
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration

...

News Releases Released on 11.19.2020
Syngene eases clients’ path to drug discovery

Anil Urs - Bengaluru

News Releases Released on 10.30.2020
Syngene International Q2 profit up 64 pc to Rs 128 cr

Press Trust of India | New Delhi

News Releases Released on 10.22.2020